Comparative Study on Alginate/chitosan Microcapsules and Montanide ISA 61 As Vaccine Adjuvants in Mice

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Apr 4

PMID 38573916

Authors

Laice A Silva

Monique F Souza

Thaynara P Carvalho

Clarissa H Santana

Andressa C Guedes

Jefferson Bruno S Oliveira

Pamela A de Lima

Paulo Roberto A Nogueira

Humberto de Mello Brandao

Tatiane A da Paixao

Renato Lima Santos

Affiliations

Soon will be listed here.

Abstract

Selection of adjuvant to be combined with the antigen is an extremely important point for formulating effective vaccines. The aim of this study was to evaluate reactogenicity, levels of IgM, IgG and subclasses (IgG1, IgG2b and IgG3), and protection elicited by vaccine formulations with association of chitosan coated alginate or Montanide ISA 61 with γ-irradiated Brucella ovis. The alginate/chitosan biopolymers as well as the Montanide ISA 61 emulsion elicited intense and long-lasting local response, especially when associated with the antigen. However, Montanide ISA 61 induced less intense reactogenicity when compared to alginate/chitosan. Furthermore, γ-irradiated B. ovis with Montanide ISA 61 induced higher levels of IgG2b an important marker of cellular immune response. In conclusion, Montanide ISA 61 resulted in milder reactogenicity when compared to the alginate/chitosan, while it induced a high IgG2b/IgG1 ratio compatible with a Th1 profile response.

References

Severino P, da Silva C, Andrade L, de Lima Oliveira D, Campos J, Souto E . Alginate Nanoparticles for Drug Delivery and Targeting. Curr Pharm Des. 2019; 25(11):1312-1334. DOI: 10.2174/1381612825666190425163424. View

Li J, Cai C, Li J, Li J, Li J, Sun T . Chitosan-Based Nanomaterials for Drug Delivery. Molecules. 2018; 23(10). PMC: 6222903. DOI: 10.3390/molecules23102661. View

Jang S, Lillehoj H, Lee S, Lee K, Park M, Bauchan G . Immunoenhancing effects of Montanide ISA oil-based adjuvants on recombinant coccidia antigen vaccination against Eimeria acervulina infection. Vet Parasitol. 2010; 172(3-4):221-8. DOI: 10.1016/j.vetpar.2010.04.042. View

Khorasani A, Madadgar O, Soleimanjahi H, Keyvanfar H, Mahravani H . Evaluation of the efficacy of a new oil-based adjuvant ISA 61 VG FMD vaccine as a potential vaccine for cattle. Iran J Vet Res. 2016; 17(1):8-12. PMC: 4898013. View

Ibrahim E, Gamal W, Hassan A, Mahdy S, Hegazy A, Abdel-Atty M . Comparative study on the immunopotentiator effect of ISA 201, ISA 61, ISA 50, ISA 206 used in trivalent foot and mouth disease vaccine. Vet World. 2016; 8(10):1189-98. PMC: 4774654. DOI: 10.14202/vetworld.2015.1189-1198. View

Braz H, Silva M, Carvalho T, da Silva L, Soares J, Barroso Costa F . Pathogenesis of Brucella ovis in pregnant mice and protection induced by the candidate vaccine strain B. Ovis ΔabcBA. Vaccine. 2022; 40(32):4617-4624. DOI: 10.1016/j.vaccine.2022.06.044. View

Carvalho T, Haddad J, Paixao T, Santos R . Meta-Analysis and Advancement of Brucellosis Vaccinology. PLoS One. 2016; 11(11):e0166582. PMC: 5112997. DOI: 10.1371/journal.pone.0166582. View

Zheng X, Yang X, Li X, Qiu G, Dai A, Huang Q . Omp16-based vaccine encapsulated by alginate-chitosan microspheres provides significant protection against Haemophilus parasuis in mice. Vaccine. 2017; 35(10):1417-1423. DOI: 10.1016/j.vaccine.2017.01.067. View

Rocha C, Silva M, Guedes A, Carvalho T, Eckstein C, Ribeiro N . Alginate-chitosan microcapsules improve vaccine potential of gamma-irradiated Listeria monocytogenes against listeriosis in murine model. Int J Biol Macromol. 2021; 176:567-577. DOI: 10.1016/j.ijbiomac.2021.02.056. View

10.

Fornefett J, Krause J, Klose K, Fingas F, Hassert R, Benga L . Comparative analysis of humoral immune responses and pathologies of BALB/c and C57BL/6 wildtype mice experimentally infected with a highly virulent Rodentibacter pneumotropicus (Pasteurella pneumotropica) strain. BMC Microbiol. 2018; 18(1):45. PMC: 5977748. DOI: 10.1186/s12866-018-1186-8. View

11.

Smits H, Abdoel T, Solera J, Clavijo E, Diaz R . Immunochromatographic Brucella-specific immunoglobulin M and G lateral flow assays for rapid serodiagnosis of human brucellosis. Clin Diagn Lab Immunol. 2003; 10(6):1141-6. PMC: 262433. DOI: 10.1128/cdli.10.6.1141-1146.2003. View

12.

Cai D, Song Q, Duan C, Wang S, Wang J, Zhu Y . Enhanced immune responses to E2 protein and DNA formulated with ISA 61 VG administered as a DNA prime-protein boost regimen against bovine viral diarrhea virus. Vaccine. 2018; 36(37):5591-5599. DOI: 10.1016/j.vaccine.2018.07.054. View

13.

Herve C, Laupeze B, Del Giudice G, Didierlaurent A, Da Silva F . The how's and what's of vaccine reactogenicity. NPJ Vaccines. 2019; 4:39. PMC: 6760227. DOI: 10.1038/s41541-019-0132-6. View

14.

Reed S, Orr M, Fox C . Key roles of adjuvants in modern vaccines. Nat Med. 2013; 19(12):1597-608. DOI: 10.1038/nm.3409. View

15.

Moreno E . The one hundred year journey of the genus Brucella (Meyer and Shaw 1920). FEMS Microbiol Rev. 2020; 45(1). DOI: 10.1093/femsre/fuaa045. View

16.

Petermann J, Bonnefond R, Mermoud I, Rantoen D, Meynard L, Munro C . Evaluation of three adjuvants with respect to both adverse effects and the efficacy of antibody production to the Bm86 protein. Exp Appl Acarol. 2017; 72(3):303-315. DOI: 10.1007/s10493-017-0156-4. View

17.

Xavier M, Paixao T, Poester F, Lage A, Santos R . Pathological, immunohistochemical and bacteriological study of tissues and milk of cows and fetuses experimentally infected with Brucella abortus. J Comp Pathol. 2008; 140(2-3):149-57. DOI: 10.1016/j.jcpa.2008.10.004. View

18.

Titball R . Vaccines against intracellular bacterial pathogens. Drug Discov Today. 2008; 13(13-14):596-600. DOI: 10.1016/j.drudis.2008.04.010. View

19.

Hua R, Huo H, Li Y, Xue Y, Wang X, Guo L . Generation and efficacy evaluation of recombinant classical swine fever virus E2 glycoprotein expressed in stable transgenic mammalian cell line. PLoS One. 2014; 9(9):e106891. PMC: 4157854. DOI: 10.1371/journal.pone.0106891. View

20.

Vasiliev Y . Chitosan-based vaccine adjuvants: incomplete characterization complicates preclinical and clinical evaluation. Expert Rev Vaccines. 2014; 14(1):37-53. DOI: 10.1586/14760584.2015.956729. View